Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

NCT03845166 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT03845166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03845166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 20, 2019
Completion date
May 31, 2027
Enrollment
325 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, hormone receptor positive breast carcinoma, metastatic castration-resistant prostate cancer, neoplasm malignant, renal cell carcinoma